Oklahoma is currently home to 859 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Oklahoma City, Tulsa, Norman and Edmond. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
NCT04633239
Recruiting
This phase I/Ib trial identifies the side effects and best dose of abemaciclib when given together with olaparib in treating patients with ovarian cancer that responds at first to treatment with drugs that contain the metal platinum but then comes back within a certain period (recurrent platinum-resistant). Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Conditions: Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Ovarian High Grade Serous Adenocarcinoma
Register for Updates
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
NCT05701917
Recruiting
This study is a prospective, multicenter, randomized controlled trial of an interventional strategy using the ClotTriever System to achieve and maintain vessel patency (ClotTriever Intervention Arm) versus conservative medical management using anticoagulation therapy alone (Conservative Medical Management Arm) in the treatment of subjects with symptomatic unilateral iliofemoral DVT. The study will collect data on demographics, comorbidities, details from the DVT diagnosis and treatment, and clin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: Saint Francis Hospital, Tulsa, Oklahoma
Conditions: Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome
Register for Updates
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
NCT06465316
Recruiting
This phase Ib trial tests the safety, side effects, and best dose of iberdomide in combination with teclistamab in treating multiple myeloma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Iberdomide is a medication that belongs to a group of drugs known as cereblon E3 ligase modulators. Iberdomide works by targeting and destroying proteins that help myeloma cancer cells to survive. A monoclonal antibody is a type of protein that ca... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Register for Updates
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
NCT04879329
Recruiting
This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants. Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic). It will also study what side effects happen when participants get the drug. A side effect is anything a drug does... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma
Conditions: Urothelial Carcinoma
Register for Updates
Protocol for Collecting, Banking and Distributing Human Tissue Samples: St. Jude Children's Research Hospital Tissue Resources Core Facility
NCT01354002
Recruiting
The aims of this protocol are: to collect and store diseased and normal tissue and body fluid samples from new and returning patients at St. Jude Children's Research Hospital (SJCRH), affiliated sites and collaborating institutions; to collect and store samples from relatives of SJCRH patients; to collect and store retrospective and prospective pertinent corresponding clinical and laboratory data on disease characterization, treatment, and outcome; and to serve as a source of human biological sa... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/05/2025
Locations: St. Jude Affiliate Clinic at Saint Francis Children's Hospital, Tulsa, Oklahoma
Conditions: Normal and Diseased Tissue and Body Fluids Samples
Register for Updates
Mevrometostat Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
NCT03460977
Recruiting
A Phase 1 Dose Escalation and Expanded Cohort Study Of PF-06821497 (Mevrometostat) in Adult Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) And Follicular Lymphoma (FL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: OU Health University of Oklahoma Medical Center, Oklahoma City, Oklahoma
Conditions: Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL), Metastatic Castration Resistant Prostate Cancer (mCRPC)
Register for Updates
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
NCT06023589
Recruiting
To assess the efficacy and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled corticosteroids (ICS) and at least one additional asthma controller medication with or without oral corticosteroids.
Gender:
ALL
Ages:
Between 5 years and 11 years
Trial Updated:
08/05/2025
Locations: Research Site, Oklahoma City, Oklahoma
Conditions: Asthma
Register for Updates
Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF
NCT05639556
Recruiting
The goal of the study is to examine multiple markers of anthropometrics, body composition, sarcopenia and frailty and compare them to dual energy X-ray absorptiometry (DXA) output, which is considered the current clinical gold-standard tool to measure body composition. The result of this study will provide detailed data regarding the nutrition and body composition within this Cystic Fibrosis population and also provide a baseline evaluation for use of these biomarkers in the future studies inclu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: University of Oklahoma Sciences Center, Oklahoma City, Oklahoma
Conditions: Cystic Fibrosis
Register for Updates
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457
Recruiting
This study is open to adults who are at least 18 years old and have: * A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or * A confirmed liver disease called metabolic-associated steatohepatitis (MASH) * BMI of 27 kg/m2 or more or * 25 kg/m2 or more if the participant is Asian. People with a history of other chronic liver diseases or high alcohol intake cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps peop... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: Options Health Research, Tulsa, Oklahoma
Conditions: Metabolic Dysfunction Associated Steatohepatitis
Register for Updates
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185
Recruiting
The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations. LY4066434 will be given alone or in combination with other treatments. The study will have 2 parts: monotherapy dose escalation and dose optimization. The study is expected to last up to approximately 5 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: University of Oklahoma - Health Sciences Center, Oklahoma City, Oklahoma
Conditions: Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
Register for Updates
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
NCT06481592
Recruiting
The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer.
Gender:
FEMALE
Ages:
Between 18 years and 70 years
Trial Updated:
08/05/2025
Locations: University of Oklahoma, Oklahoma City, Oklahoma
Conditions: Endometrial Cancer
Register for Updates
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
NCT06303505
Recruiting
The purpose of this multicentric, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the best dose of TUB-040 in patients with ovarian cancer and Non Small Cell Lung Cancer. TUB-040 is an antibody-drug-conjugate which delivers a topoisomerase I inhibitor to tumor cells which overexpress the target NaPi2b. The study consists of two parts: In dose escalation, ovarian cancer patients and lung cancer patients rece... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma
Conditions: Ovarian Cancer, Non-small Cell Lung Cancer
Register for Updates